Physician profile
Zane Cooke
NPI 1134515976
$9,405.64
in general payments reported to CMS, 2019-2025
40 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $991 · 2021: $1,192 · 2022: $1,106 · 2023: $1,689 · 2024: $1,620 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,738.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,361.64 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $807.78 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $666.79 | 2020-2025 | |
| Amgen INC. | $650.03 | 2019-2025 | Otezla, Repatha, Evenity |
| Otsuka America Pharmaceutical, INC. | $573.50 | 2021-2025 | Rexulti |
| Esperion Therapeutics, INC. | $518.44 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $479.21 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $333.12 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $320.93 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $282.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $232.64 | 2022-2025 | |
| Axsome Therapeutics, INC. | $161.58 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.31 | 2019-2020 | |
| Exact Sciences Corporation | $141.95 | 2023-2024 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zane Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.